Research

HOME > RESEARCH

In This Section

With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.

LATEST NEWS

April 16, 2024 — New SPECT/CT Technique Shows Impressive Biomarker Identification, Offers Increased Access for Prostate Cancer Patients
A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment, according to new research in JNM.
April 11, 2024 — PET/MRI Accurately Classifies Prostate Cancer Patients, Offers Potential to Avoid Unnecessary Biopsies
PET/MRI can improve diagnostic accuracy for prostate cancer patients and help avoid unnecessary biopsies, according to new research published in JNM.
April 3, 2024 — Novel Theranostic Tool Allows for Noninvasive Identification and Treatment of Ovarian Cancer
A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of JNM.
March 25, 2024 — UPTAKE: A Dialogue with Future Leaders
This fall, SNMMI-TS member Jacquelyn Brogley visited nuclear medicine students at her alma mater, Gateway Community College in Phoenix, AZ. Hear her advice to them and how the day left her inspired for the future of the field.
March 11, 2024 — New Method for Triggering and Imaging Seizures Can Help Guide Epilepsy Surgery
Researchers have developed a new method for triggering and imaging seizures in epilepsy patients, offering physicians the ability to collect real-time data to tailor epilepsy surgery, according to new research published in The Journal of Nuclear Medicine.
March 7, 2024 — Novel PET Tracer Maps Fructose Metabolism to Identify Cardiac and Neural Disorders
A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in The Journal of Nuclear Medicine.
March 5, 2024 — Message from the President
SNMMI President Helen Nadel highlights recent achievements, global collaborations, advocacy efforts, and upcoming SNMMI meetings.
March 5, 2024 — Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Newly Diagnosed Prostate Cancer Patients
Radioguided surgery can detect and remove metastatic pelvic lymph nodes in patients newly diagnosed with prostate cancer, according to research published in the March issue of The Journal of Nuclear Medicine.

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities. Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.